In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge at www.bms.com or by directing a request to Bristol Myers Squibb, Office of the Corporate Secretary, 430 East 29th Street, 14th Floor, New York, New York 10154-0037. 0000004547 00000 n . Elizabeth Mily joined Bristol Myers Squibb Co. as executive vice president of strategy and business development in March 2020 after 27 years in investment banking. 0000002184 00000 n bristol myers squibb holiday calendar 2021. The FDA has assigned a PDUFA goal date of September 10, 2022. Add to Microsoft Outlook. (link). Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. A replay of the webcast will be available on http://investor.bms.com approximately three hours after the conference call concludes. All comparisons are made versus the same period in 2021 unless otherwise stated. 0 Here we feature several BMS colleagues sharing their views on the subject from their perspectives, based on their own experiences. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Youll find valuable developmental opportunities to help connect you to your passion and drive your career forward. And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. Both GAAP and non-GAAP guidance assume current exchange rates. 0000015083 00000 n 0000042941 00000 n 3 floating holidays. Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, Standards of Business Conduct and Ethics. In addition, non-GAAP gross margin, which is gross profit excluding certain specified items as a percentage of revenues, non-GAAP operating margin, which is operating income excluding certain specified items as a percentage of revenues; non-GAAP free cash flow, which is non-GAAP net earnings plus adjustments related to cash generated from operating activities and cash paid for capital expenditures; non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expense excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results. 0000000016 00000 n Learn about Bristol Myers Squibb Vacation & Paid Time Off, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. Sales from key loss of exclusivity (LOE) brands, which represent. There are regular US holidays with 4 floating holiday/personal days. Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Barclays Virtual Global Healthcare Conference, which will Shares of Bristol Myers Squibb Co. BMY, -0.22% sank 0.22% to $66.77 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX, Glassdoor is your resource for information about the Vacation & Paid Time Off benefits at Bristol Myers Squibb. Bristol Myers Squibb is well positioned to build on our success in 2021 and continue to grow our company through the end of the decade. Cafeteria and catering services offering healthy options. Best place for vacation and time off, BMS incentivize family time. No cons. Cautionary Statement Regarding Forward-Looking Statements. In November, the company announced that the U.S. Food and Drug Administration (FDA) has extended the review of the New Drug Application (NDA) for mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy to April 28, 2022. they used to have flexible schedules- though that is unfortunately being phased out. 0000192949 00000 n Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. A method of treating a disorder mediated by BRD9 comprising administering an effective amount of a compound of Formula: or a pharmaceutically acceptable salt thereof This earnings release and the accompanying tables also provide certain revenues and expenses as well as non-GAAP measures excluding the impact of foreign exchange. This information is among the primary indicators that we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. System. Meet Our Team in Tampa, FL Meet Our Team in Tampa, FL Possibility Lives at BMS Find out why possibility lives at Bristol Myers Squibb Asha on Skills 2 Give Volunteer Program Asha on Skills 2 Give Volunteer Program 0000005488 00000 n All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. ET. In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). There are no upcoming events. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-nave and pre-treated patients. After the war and into the 1960s, both Squibb and Bristol-Myers expanded their production and research of antibiotics. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Former Sales Training Manager in nullnull, Current Maintenance Engineer in Manati, PR, Puerto Rico, Current Senior Manufacturing Engineer in New Brunswick, NJ, New Jersey, Former Senior Financial Analyst in Princeton, NJ, New Jersey. 0000193438 00000 n We are proud of our companys global commitment to Inclusion & Diversity and the meaningful steps we are taking to drive equitable advancement and outcomes for all. Major Holidays. These items are excluded from non-GAAP earnings and related EPS information because the company believes they neither relate to the ordinary course of the companys business nor reflect the companys underlying business performance. In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, the company and Turning Point Therapeutics file annual, quarterly and special reports, proxy statements and other information with the SEC. Turning Point Therapeutics lead asset, repotrectinib, is a next-generation, potential best-in-class tyrosine kinase inhibitor (TKI) targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer (NSCLC) and other advanced solid tumors. The recognition is a testament to our commitment to transform patients lives through science. Is Bristol Myers Squibb (BMY) Stock Outpacing Its Medical Peers This Year? The news made me sad as I found her career path quite inspiring The variability of the specified items may have a significant and unpredictable impact on our future GAAP results. customer.relations@bms.com (877) 517-6326 (Monday-Friday, 8 AM-8 PM ET) Adverse event or product quality complaints (800) 721-5072 )yJP #BMSCareers. ET on April 29, 2021 Bristol-Myers Squibb (NYSE:BMY) SVP Adam Dubow sold 3,119 shares of the business's stock in a transaction dated Wednesday, May 5th. 0000006494 00000 n Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Monthly calendar; Candle-lighting times only . The transaction supports Bristol Myers Squibbs medium- to long-term growth strategy with accretion to non-GAAP earnings per share (EPS) beginning in 2025. Available to US-based employeesChange location, Comparable to many others in the same league. Whether recruiting from academia or the commercial biopharma sector, Mihaela explains why a move to BMS is a great career move. We claim: 1. Income tax benefit was approximately $510 million despite pre-tax earnings of $1.9 billion in the quarter primarily due to the impact of internal transfers of certain intangible assets of $1.0 billion. 05/21/2021. Manage cover for holidays and absenteeism for warehouse staff through Time Management. Materials on this website may contain information about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. We regularly promote awareness of this resource to employees. Amortization of acquired intangible assets decreased 4% to $2.4 billion in the quarter primarily due to an extended marketed product rights exclusivity period. Kitchenettes with vending machines, free coffee and tea. We are committed to following all laws regarding child labor, forced labor and freedom of association. (This May 18 story corrects payment value in headline and first paragraph to $1.56 billion from $1.38 billion) (Reuters) - Drugmaker Bristol Myers (NYSE: BMY) Squibb Feb 07, 2021, 01:50 AM. 0000043468 00000 n We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. 2020; 2022 Calendar Settings. General Manager Development: We partner with the premier CEDEP organization to build our future General Manager talent through this internationally recognized program. If you have $1,000 at the ready, pharmaceutical stock Bristol Myers Squibb *Stock Advisor returns as of June 7, 2021. Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in the press release that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. Bristol Myers Squibb (BMY) posted disappointing results in the first quarter as the pharmaceutical companys revenues rose 3% Shrilekha Pethe Apr 30, 2021. Upcoming events. For more information, call BMS Access Support at 1-800- 861- 0048, 8 am to 8 pm ET, Monday - Friday. bristol myers squibb Dublin, Ireland . Month List Download. These documents will be available at no charge on the SECs website at www.sec.gov. Add to iCalendar. U.S. revenues increased 11% to $7.5 billion in the quarter. Since our founding, we have leveraged our deep scientific expertise to develop a pipeline of promising precision oncology assets, said Athena Countouriotis, M.D., President and Chief Executive Officer, Turning Point Therapeutics. Headquarters Location 430 E. 29th Street 14th Floor New York, New York, 10016, United States The website may also contain certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. 0000012839 00000 n Learn about our safety approach to COVID-19 >. These items are excluded from non-GAAP earnings and related EPS information because Bristol Myers Squibb believes they neither relate to the ordinary course of Bristol Myers Squibbs business nor reflect Bristol Myers Squibbs underlying business performance. Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company committed to discovering, developing, and delivering medicines that help patients prevail over serious diseases. Your response will be removed from the review this cannot be undone. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Working among other smart, creative and talented colleagues, youll find support and uncommon opportunities to learn, grow and lead. Worldwide revenues are expected to be approximately $47 billion, representing an increase in the low-single digits. Glassdoor is your resource for information about the Vacation & Paid Time Off benefits at Bristol Myers Squibb. Bristol Myers Squibb Bristol Myers Squibb expects repotrectinib to be approved in the U.S. in the second half of 2023 and become a new standard of care for patients with ROS1-positive NSCLC in the first-line setting. MORAb-202 is Eisais first ADC and combines Box 4000, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, for and on behalf of itself and its Affiliates Bristol Myers Squibb (NYSE: BMY) recently picked up another U.S. Food and Drug Administration (FDA) approval for Zeposia in The firm is expected to announce its next quarterly earnings report on Thursday, August 5th. Learn about joining our global team! Media: media@bms.com Apr 2021 - Oct 2022 1 year 7 months. With repotrectinib, we have the opportunity to change the standard of care and address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients., Through this transaction, we will be able to harness the full potential of our precision oncology platform to advance the standard of care for cancer patients. startxref I am proud of how our company performed in 2021, helping more patients across our therapeutic areas, while achieving 9% revenue and 17% non-GAAP EPS growth, respectively, said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. Leixlip, Kildare. NEW YORK--(BUSINESS WIRE)-- Whether it's bringing key medicines to market, or expanding patient access to medicines, our commitment to patients drives innovation in our pipeline and guides our action as a responsible corporate citizen. 0000004898 00000 n We believe in a Total Rewards experience that enriches your life today and engages and empowers you to save, perform, grow, and build toward all of your tomorrows. I'm ready to enroll! Stress management, well-being, and integrating work with life all determine the energy we bring each day to our work, family and community. Forward-looking statements in this earnings release should be evaluated together with the many risks and uncertainties that affect the companys business and market, particularly those identified in the cautionary statement and risk factors discussion in the companys Annual Report on Form 10-K for the year ended December 31, 2020, as updated by the companys subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. Choosing Your Medical Plan. trailer Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the companys most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. The accounting treatment as a business combination or asset acquisition will be determined upon the expected close of the transaction in the third quarter of 2022. Compliance with data privacy laws on a global basis is an essential business practice for Bristol Myers Squibb. Turning Point Therapeutics 867 0 obj In addition, the non-GAAP financial guidance in this communication excludes the impact of any potential additional future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; changes to tax and importation laws and other restrictions in the United States, the European Union and other regions around the world that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; challenges inherent in new product development, including obtaining and maintaining regulatory approval; the companys ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; the risk of certain novel approaches to disease treatment (such as CAR T therapy); industry competition from other manufacturers; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products, including without limitation, interruptions caused by damage to the companys and the companys suppliers manufacturing sites; the impact of integrating the companys and Celgenes business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the companys suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; regulatory decisions impacting labeling, manufacturing processes and/or other matters; the impact on the companys competitive position from counterfeit or unregistered versions of its products or stolen products; the adverse impact of cyber-attacks on the companys information systems or products, including unauthorized disclosure of trade secrets or other confidential data stored in the companys information systems and networks; the companys ability to execute its financial, strategic and operational plans; the companys ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; the companys dependency on several key products; any decline in the companys future royalty streams; the companys ability to effectively manage acquisitions, divestitures, alliances and other portfolio actions and to successfully realize the expected benefits of such actions; the companys ability to attract and retain key personnel; the impact of the companys significant additional indebtedness that it incurred in connection with the Celgene acquisition and the MyoKardia acquisition; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; the impact of adverse outcomes in lawsuits, claims, proceedings and government investigations; the impact of our exclusive forum provision in our by-laws for certain lawsuits on our stockholders ability to obtain a judicial forum that it finds favorable for such lawsuits; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic on the companys operations. 0000013257 00000 n Shareholders. For your convenience, we provide daily services that save you time. Moving to the bottom line, Bristol Myers Squibb grew its non-GAAP EPS by 22.7% YOY to $2.00 in the third quarter. Listen to Webcast. paid time off and holidays- employees are expected to work holidays at times. , bristol myers squibb holiday calendar 2021 2021, bristol myers squibb holiday calendar 2021, Cigna Behavioral Health Provider Phone Number, A Person Will Become Responsible If He/she Is Brainly, Classes Offered At Gateway Community College. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. The 2022 non-GAAP EPS guidance is further explained under Use of Non-GAAP Financial Information. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. The company has a current ratio of 1.67, a quick ratio of 1.58 and a debt-to-equity ratio of 0.82. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by using this link which becomes active 15 minutes prior to the scheduled start time and entering your information to be connected. Year. Our people Our global workforce is made up of over 26,000 passionate people who, in 2021, helped Pandora record the highest earnings to date, led by a refreshed long-term growth strategy. No forward-looking statement can be guaranteed.